| P50 | author | Christian C. Abnet | Q30506443 |
| | Ruth Pfeiffer | Q90909936 |
| P2093 | author name string | Linda M Liao | |
| | Neal D Freedman | |
| | Michael B Cook | |
| | Cindy Ke Zhou | |
| | Sarah E Daugherty | |
| P2860 | cites work | Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues | Q28192400 |
| | Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone | Q33715171 |
| | Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials | Q33767211 |
| | Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy | Q36267681 |
| | Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort | Q36478226 |
| | Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy | Q36510749 |
| | Contribution of platelets to tumour metastasis. | Q37831798 |
| | Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study | Q38965797 |
| | Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial | Q39558136 |
| | Impact of aspirin on clinical outcomes for African American men with prostate cancer undergoing radiation. | Q40474835 |
| | Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo | Q40859728 |
| | Imputing missing covariate values for the Cox model | Q41149368 |
| | Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial | Q41670120 |
| | The use of aspirin and the risk of mortality in patients with prostate cancer | Q41738438 |
| | Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model | Q42461163 |
| | Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate | Q42494161 |
| | Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. | Q43163981 |
| | A cohort study investigating aspirin use and survival in men with prostate cancer | Q45080125 |
| | Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy | Q46088127 |
| | Aspirin Use Reduces the Risk of Aggressive Prostate Cancer and Disease Recurrence in African-American Men. | Q46176546 |
| | Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. | Q46186672 |
| | Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer | Q48188461 |
| | Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink. | Q54484100 |
| | Design and serendipity in establishing a large cohort with wide dietary intake distributions : the National Institutes of Health-American Association of Retired Persons Diet and Health Study | Q77355366 |
| | Effects of non-selective non-steroidal anti-inflammatory drugs on the aggressiveness of prostate cancer | Q81775097 |
| | Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy | Q83143261 |
| P433 | issue | 7 | |
| P921 | main subject | aspirin | Q18216 |
| P304 | page(s) | 410-420 | |
| P577 | publication date | 2017-05-15 | |
| P1433 | published in | Cancer Prevention Research | Q2665103 |
| P1476 | title | Do Aspirin and Other NSAIDs Confer a Survival Benefit in Men Diagnosed with Prostate Cancer? A Pooled Analysis of NIH-AARP and PLCO Cohorts | |
| P478 | volume | 10 | |